What it's for (Indications)
- Imidapril is indicated for the treatment of essential hypertension, either as monotherapy or in combination with other antihypertensive agents.
- It is effective in reducing blood pressure through its action on the renin-angiotensin-aldosterone system.
- This involves a complex cascade of events that ultimately leads to systemic vasodilation and a reduction in fluid retention.
- Additionally, imidapril is used in the management of congestive heart failure, particularly in patients who exhibit symptomatic heart failure, to improve patient outcomes and alleviate symptoms.
- Its use in heart failure is predicated on its ability to reduce both preload and afterload on the heart, thereby improving cardiac efficiency, reducing myocardial workload, and mitigating disease progression.
- The selection of imidapril for these conditions should be based on a comprehensive assessment of the patient's clinical status, severity of the condition, and presence of comorbidities.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of imidapril must be individualized based on the patient's clinical response, renal function, and tolerance, with careful consideration of the patient's blood pressure targets and underlying medical conditions. Initial doses are typically low and gradually titrated upwards to achieve the desired therapeutic effect while minimizing adverse reactions. For essential hypertension, the usual starting dose may vary, followed by adjustments according to the blood pressure response and patient tolerability. In patients with congestive heart failure or renal impairment, lower initial doses and slower titration may be necessary to prevent acute hypotension or worsening renal function. Regular monitoring of blood pressure, renal function (serum creatinine, blood urea nitrogen), and serum electrolytes (especially potassium) is essential throughout the treatment period. Dosage adjustments may also be required when co-administering with diuretics or other antihypertensive agents, or in elderly patients who may be more sensitive to the effects of the drug. |
Safety & Warnings
Common Side Effects
- Common side effects associated with imidapril include a persistent, dry cough, which is a class effect of ACE inhibitors and typically resolves upon discontinuation of therapy.
- Other frequently reported adverse reactions include dizziness, lightheadedness, and headache, often related to the antihypertensive effect, particularly during initial dosing or dose titration.
- Fatigue and asthenia may also occur, impacting daily activities.
- More serious, though less common, adverse effects include angioedema (swelling of the face, lips, tongue, or larynx), which can be life-threatening due to potential airway obstruction and requires immediate medical attention and drug discontinuation.
- Hyperkalemia, especially in patients with renal impairment, diabetes, or those receiving potassium-sparing diuretics or potassium supplements, is another significant concern that necessitates electrolyte monitoring.
- Renal impairment or acute renal failure, symptomatic hypotension (particularly in volume-depleted patients), and allergic reactions such as rash and pruritus are also potential side effects that necessitate careful monitoring and management by a healthcare professional.
Serious Warnings
- Black Box Warning: ACE inhibitors, including imidapril, can cause injury and death to the developing fetus when administered to pregnant women. Exposure to drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy has been associated with fetal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios, which can result from decreased fetal renal function, has also been reported and is associated with fetal lung hypoplasia and skeletal deformations. When pregnancy is detected, imidapril should be discontinued as soon as possible. It is crucial to inform female patients of childbearing age about the potential risks to the fetus if they become pregnant while on imidapril. Patients planning pregnancy should be counselled about the risks associated with imidapril and should be switched to appropriate alternative antihypertensive treatments during pregnancy to ensure both maternal and fetal safety. This warning is critical for patient safety and compliance, emphasizing the severe teratogenic potential.
- Patients receiving imidapril should be closely monitored for several important warnings.
- Symptomatic hypotension, particularly after the initial dose or following a diuretic dose increase, can occur, especially in patients who are volume-depleted, salt-depleted, or with severe congestive heart failure; this necessitates careful dose titration and monitoring.
- Renal function should be regularly assessed, as ACE inhibitors can cause reversible elevations in serum creatinine and blood urea nitrogen, particularly in patients with pre-existing renal impairment, severe congestive heart failure, or bilateral renal artery stenosis (or unilateral stenosis in a solitary kidney), potentially leading to acute renal failure.
- Hyperkalemia is a significant risk, especially in patients with renal dysfunction, diabetes, or those concurrently using potassium-sparing diuretics, potassium supplements, or other drugs that increase serum potassium.
- The potential for angioedema, while also a contraindication for re-challenge, is a critical warning during initial therapy, manifesting as swelling of the face, extremities, lips, tongue, glottis, and/or larynx, which requires immediate discontinuation and emergency treatment.
- Neutropenia/agranulocytosis has been reported with ACE inhibitors, particularly in patients with renal impairment and collagen vascular disease, necessitating periodic monitoring of white blood cell counts.
How it Works (Mechanism of Action)
Imidapril is an angiotensin-converting enzyme (ACE) inhibitor that exerts its therapeutic effects by blocking the conversion of inactive angiotensin I to the potent vasoconstrictor angiotensin II. This inhibition leads to several profound physiological changes within the cardiovascular and renal systems. Firstly, the reduction in circulating angiotensin II levels results in systemic vasodilation, which subsequently lowers total peripheral vascular resistance and, consequently, blood pressure. Secondly, by suppressing angiotensin II, the secretion of aldosterone from the adrenal cortex is significantly decreased. This leads to diminished sodium and water reabsorption in the renal tubules and reduced potassium excretion, further contributing to a decrease in fluid volume and blood pressure. Furthermore, ACE is also responsible for the degradation of bradykinin, a potent endogenous vasodilator. Inhibition of ACE by imidapril leads to increased levels of bradykinin, further contributing to vasodilation and the antihypertensive effect. This bradykinin accumulation is also believed to be responsible for the common side effect of cough and the serious adverse event of angioedema associated with ACE inhibitors. The overall effect is a beneficial reduction in both preload and afterload on the heart, making it an effective treatment in both hypertension and heart failure.
Commercial Brands (Alternatives)
No other brands found for this formula.